Currently, there is a predominance of studies related to the use of anti-IL-5 in asthma when compared to its use in CRS.50, 51 In this context, Cochrane’s systematic review52 reveals the robustness of the available evidence, despite some variability in the severity of cases, outcomes, and follow-up time. This evidence concerns the gene IL5 and congenital rubella syndrome.